EUPROTEIN has developed and validated LAG3 and FGL1 proteins that could be used in the studies of the interaction between LAG3 and FGL1, pathways associated with these two proteins, and potentially drug screening.
Fibrinogen-like protein 1 (FGL1) is a member of the fibrinogen family of proteins, which also includes fibrinogen, fibrinogen-like protein 2, and clotting factors V, VIII, and XIII. FGL1 is homologous to the carboxy terminus of the fibrinogen beta- and gamma- subunits which contains the four conserved cysteines of that are common to all members of the fibrinogen family. However, FGL1 lacks the platelet-binding site, cross-linking region, and thrombin-sensitive site which allow the other members of the fibrinogen family to aid in fibrin clot formation.
FGL1 plays a role in hepatocytes. Under normal physiological conditions, FGL1 is primarily secreted from hepatocytes and contributes to its mitogenic and metabolic functions. It may play a role in the development of hepatocellular carcinomas.
FGL1 is also an immune suppressive molecule that inhibits antigen-specific T-cell activation by acting as a major ligand of lymphocyte-activation gene 3 (LAG3), responsible for the T-cell inhibitory function of LAG3. The identification of FGL1 as a ligand of LAG3 may spark studies of other ligands involved in immune suppressive and potentially cancer immunotherapies.
EUPROTEIN has developed and validated LAG3 and FGL1 proteins that could be used in the studies of the interaction between LAG3 and FGL1, pathways associated with these two proteins, and potentially drug screening. These high-quality proteins can also serve as references in immunoassay kits that quantify LAG3-FGL1 binding capabilities.
Or if you need help expressing LAG3 or FGL1 proteins or generating antibodies against them, please submit your inquiry by clicking the button below. Our service representative will get back to you promptly to discuss your project needs.